The global single-photon emission computed tomography market size reached USD 2.28 Billion in 2021 and it is expected to enjoy a valuation of USD 2.45 Billion by the end of 2022. Furthermore, with the rising prevalence of various cardiovascular diseases and the growing need for better diagnostic technologies, the overall demand for single-photon emission computed tomography (SPECT) is poised to grow at 6.9% CAGR between 2022 and 2032, totaling a market valuation of ~USD 4.76 Billion by 2032.
Based on product, the single imaging gamma cameras segment dominated the global single-photon emission computed tomography market with a market share of about 75.5% in 2021 and it is likely to retain its dominance during the projected period.
Single-photon emission computed tomography is a potential nuclear medicine technique that produces 3-D images of functional processes in the human body while allowing non-invasive diagnostic imaging of metabolic processes using short-lived radioisotopes. Applications for single-photon emission computed tomography scanners are numerous and one key application is the detection of chronic illnesses.
Nuclear imaging apparatus includes single-photon emission computed tomography imaging systems. Single-photon emission computed tomography is used to assess the metabolic and functional data of cells and organs as it relates to disease processes. Enhancing various equipment's diagnostic capabilities in organic-specific or dual-modality systems has recently been crucial, and is anticipated to fuel market expansion during the projection period.
| Attribute | Key Statistics |
|---|---|
| Single Photo Emission Computed Tomography Market Base Value (2021) | USD 2.28 Billion |
| Estimated Market Value (2022) | USD 2.45 Billion |
| Projected Market Value (2032) | USD 4.76 Billion |
| Value-based CAGR (2022 to 2032) | 6.9% |
| Market Share of Top 5 Countries | 59.3% |
The single-photon emission computed tomography (SPECT) systems market is driven by the rising prevalence of cancer, neurological diseases, and cardiovascular diseases.
Similarly, rising patient awareness, an increasing number of initiatives for research and development, and a rise in demand for diagnostic imaging devices such as MRI and X-ray devices are expected to boost the market during the forecast period. The overall single-photon emission computed tomography holds approximately 6.1% of the global medical imaging market which stood at USD 37.2 Billion in 2021.
The global single-photon emission computed tomography market expanded at a CAGR of 5.4% during the historic period from 2012 to 2021. However, with the growing demand for effective diagnostic techniques, the overall sales of single-photon emission computed tomography products are likely to grow at 6.9% CAGR through 2032.
Demand for single-photon emission computed tomography scanners in cancer diagnosis has increased significantly over the past few years and the trend is likely to continue during the forecast period. The technology offers a sophisticated diagnostic tool that helps in early disease diagnosis coupled with the capability to detect disease progression at each stage.
Cancer is one of the leading causes of death in many countries around the globe, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.
Industry experts have noted that the diagnostic accuracy of single-photon emission computed tomography scanners in certain clinical oncological examinations such as lung cancer, prostate cancer, colorectal cancer, melanoma, and several other cancers is higher than other diagnostic imaging techniques.
Manufacturers are concentrating on integrating several technological advancements into their single-photon emission computed tomography scanning machines, including higher storage capacity and increased efficiency about faster scanning times.
From a business perspective, increased data storage will enable physicians to archive more information from patients' prior scans, track tumor development over the course of a patient's disease prognosis, and perform more scans per day, increasing the financial viability of single-photon emission computed tomography scanners in the nuclear medicine industry.
Growing Application of Single-Photon Emission Computed Tomography in Various Medical Fields and Advancements in radiopharmacy to Boost Market
Globally, single-photon emission computed tomography (SPECT) and X-ray transmission computed tomography (CT) scan hybrid imaging is becoming more popular. With the exact attenuation correction and fusion imaging that this cutting-edge technology offers, diagnostic sensitivity, and specificity are increased.
By defining prognostic and treatment monitoring capabilities and metabolic information provided by traditional nuclear imaging methods, the combination of SPECT and CT aids in improved disease staging. As a result, SPECT/CT has increasingly been used in clinical tests, particularly in the areas of musculoskeletal, cardiology, endocrinology, cancer, infection, and others.
Due to their use in creating a customized treatment plan for individualized treatment, multimodality imaging techniques will further change diagnostic imaging procedures in the future.
The practice of nuclear medicine has changed dramatically over the past ten years as a result of amazing developments in radiopharmacy, instrumentation, and information technology, all of which have played significant roles in fostering the field's expansion.
The field of nuclear medicine has been revived by new technologies like PET/CT and SPECT/CT. It is also anticipated that the development of novel radiopharmaceuticals and other hybrid modalities, like SPECT/MRI, would spur the development of new diagnostic and therapeutic uses.
All the above scenarios offer a great opportunity for market growth during the forecast period from 2022 to 2032.
The expansion of the single-photon emission computed tomography market over the projection period may be constrained by the lower availability and insufficient supply of molecular isotopes, which are necessary for diagnostic imaging devices.
For instance, there have been numerous supply shortages for technetium and molybdenum during the past few years, which are used in the bulk of SPECT operations in cardiology. Due to aging and safety concerns, the Canadian reactors that supply the molecular isotopes were permanently shut down in 2016, which limited the supply.
The field of nuclear medicine imaging has reached milestones with the advent of hybrid/fusion scanners which are paving the way to a new era in the field of imaging.
The introduction of new radiation detector systems in nuclear medicine imaging has led to a multifold increase in sensitivity and energy resolution. With the use of CZT (cadmium zinc telluride) detectors, SPECT/CT is likely to become organ-specific.
Similarly, the higher price of SPECT devices, such as SPECT-CT, SPECT-MRI, and the integration and combination of various diagnostics and imaging devices is usually a major cost restraint for the single-photon emission computed tomography market.
Only professionals who are trained within the healthcare domain for day-to-day operations and maintenance can work on single-photon emission computed tomography devices. Globally, the demand for SPECT devices is increasing. The shortage of trained specialists and professionals will hamper the growth of the global single-photon emission computed tomography market over the forecast period.
These factors cumulatively propose a negative effect on the developmental growth of the single-photon emission computed tomography market.
Presence of Favourable Reimbursement Policies Boosting Market in the USA
The USA holds approximately 38.0% share in the global single-photon emission computed tomography market in 2021 and is projected to grow at a robust pace during the forecast period.
Favorable reimbursement for nuclear medicine devices and treatment is increasing in North America which is expected to boost the growth of the United States of America single-photon emission computed tomography market.
The percentage of the total payor mix from private/self-pay revenue increased from 66.5% in 2018 to 67.4% in 2020. The Medicare percentage decreased from 21.8% to 20.5%.
Rapid Expansion of Healthcare Infrastructure Generating demand in China
With a market share of over 5.3% in 2021 in the global market, China's single-photon emission computed tomography market is anticipated to grow at a healthy pace throughout the forecast period.
This expansion is attributed to the country's fast-developing medical infrastructure, an increase in scientific research on the diagnosis, treatment, and follow-up of chronic illnesses, as well as significant support from the public and commercial sectors for cancer research.
Rising Geriatric Population Driving Market in Germany
As per FMI, Germany is set to hold a market share of nearly 5.0% in the global single-photon emission computed tomography market during the forecast period owing to an increase in the elderly population, increased prevalence of cancer, clinical usage of diagnostics techniques that use radiopharmaceuticals and increasing funding from the government.
40-59-year-olds make up the largest age group in Germany, at 23 million people. The most recent figures from 2021 confirm that the next-largest age group was 65 years and older, at 18.44 million.
Demand to Remain High for Single Imaging Cameras
The single imaging gamma cameras segment held a market share of about 75.5% in the global market in 2021 and it is expected to grow at a CAGR of 6.3% throughout the forecast period.
The most used imaging tool in nuclear medicine is the gamma camera, often known as a scintillation camera. It allows the capture of both dynamic and static images of the area of interest in the human body. Thus single-imaging gamma cameras are ahead of other products in the single-photon emission computed tomography market.
Growing Popularity of SPECT in Cardiology to Generate Maximum Revenues
Based on application, the cardiology segment held a revenue share of around 36.6% in the global single photon emission computed tomography market in 2021 and is expected to expand at a moderate growth rate over the forecast period.
Cardiologists utilize single-photon emission computed tomography to see how the blood flows through various areas of the heart. Doctors can see where and how well blood flows into and around the heart by injecting a radioactive tracer (such as technetium or sestamibi) that has been marked with gamma cameras.
In this ailment, medical professionals determine whether a patient's heart has been negatively affected by conditions such as hypertension, coronary artery disease, atherosclerosis (artery hardening), valvular diseases like mitral valve prolapse, congenital bicuspid valves brought on by infection in early childhood, etc.
Most of the SPECT Product Sales Remain Concentrated in Hospitals
The hospital's segment held a 56.9% market share in the single-photon emission computed tomography market in 2021 and it is expected to grow at a CAGR of 7.6% during the forecast period, owing to the easy access and availability of SPECT products across hospitals for cardiology and oncology treatments.
The SPECT market will boost due to a large number of patients being admitted to the hospital for seeking treatment. The availability of advanced medical equipment with improved efficiency and technology along with trained staff and healthcare professionals add to the high growth of this segment.
Similarly, the presence of advanced medical equipment attracts a large number of patients to come to hospitals to seek treatment and get maximum satisfaction and relief. Thus hospitals are ahead of other end users in the single-photon emission computed tomography market.
To establish a dominant position in the market, major players in the single-photon emission computed tomography market are aggressively concentrating on partnerships, product launches, and expansion.
For instance
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | USD 2.45 Billion |
| Projected Market Size (2032) | USD 4.76 Billion |
| Anticipated Growth Rate (2022 to 2032) | 6.9% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, Russia, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, Israel, North Africa, and South Africa |
| Key Market Segments Covered | Product, Application, End User, and Region |
| Key Companies Profiled | Bruker Corp.; DDD-Diagnostic AS; Digmed Corp.; General Electric Co.; Mediso Ltd.; MiE GmbH; MILabs BV; Siemens Healthineers AG; Spectrum Dynamics Medical Inc.; GE Healthcare; CardiArc; Beijing Hamamatsu Photon Techniques INC.; SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.; PNPMed; NuCare Inc. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Table 01: Global Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 02: Global Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 03: Global Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 04: Global Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Table 05: Global Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Region
Table 06: North America Market Value (US$ Million) Analysis 2012 to 2032and Forecast 2022 to 2032, by Country
Table 07: North America Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 08: North America Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 09: North America Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 10: North America Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Table 11: Latin America Market Value (US$ Million) Analysis 2012 to 2032and Forecast 2022 to 2032, by Country
Table 12: Latin America Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 13: Latin America Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 14: Latin America Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 15: Latin America Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Table 16: Europe Market Value (US$ Million) Analysis 2012 to 2032and Forecast 2022 to 2032, by Country
Table 17: Europe Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 18: Europe Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 19: Europe Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 20: Europe Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Table 21: South Asia Market Value (US$ Million) Analysis 2012 to 2032and Forecast 2022 to 2032, by Country
Table 22: South Asia Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 23: South Asia Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 24: South Asia Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 25: South Asia Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Table 26: East Asia Market Value (US$ Million) Analysis 2012 to 2032and Forecast 2022 to 2032, by Country
Table 27: East Asia Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 28: East Asia Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 29: East Asia Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 30: East Asia Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Table 31: Oceania Market Value (US$ Million) Analysis 2012 to 2032and Forecast 2022 to 2032, by Country
Table 32: Oceania Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 33: Oceania Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 34: Oceania Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 35: Oceania Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Table 36: MEA Market Value (US$ Million) Analysis 2012 to 2032and Forecast 2022 to 2032, by Country
Table 37: MEA Market Value (US$ Million) Analysis and Forecast 2012 to 2032, By Product
Table 38: MEA Market Volume (Units) Analysis and Forecast 2012 to 2032, By Product
Table 39: MEA Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by Application
Table 40: MEA Market Value (US$ Million) Analysis and Forecast 2012 to 2032, by End User
Figure 01: Global Volume (Units), 2012 to 2021
Figure 02: Global Volume (Units) & Y-o-Y Growth (%) Analysis, 2022 to 2032
Figure 03: , Pricing Analysis per unit (US$), in 2022
Figure 04: , Pricing Forecast per unit (US$), in 2032
Figure 05: Global Value (US$ Million) Analysis, 2012 to 2021
Figure 06: Global Forecast & Y-o-Y Growth, 2022 to 2032
Figure 07: Global Absolute $ Opportunity (US$ Million) Analysis, 2021 to 2032
Figure 08: Global Value Share (%) Analysis 2022 and 2032, By Product
Figure 09: Global Y-o-Y Growth (%) Analysis 2021 to 2032, By Product
Figure 10: Global Attractiveness Analysis 2022 to 2032, By Product
Figure 11: Global Value Share (%) Analysis 2022 and 2032, by Application
Figure 12: Global Y-o-Y Growth (%) Analysis 2021 to 2032, by Application
Figure 13: Global Attractiveness Analysis 2022 to 2032, by Application
Figure 14: Global Value Share (%) Analysis 2022 and 2032, by End User
Figure 15: Global Y-o-Y Growth (%) Analysis 2021 to 2032, by End User
Figure 16: Global Attractiveness Analysis 2022 to 2032, by End User
Figure 17: Global Value Share (%) Analysis 2022 and 2032, by Region
Figure 18: Global Y-o-Y Growth (%) Analysis 2021 to 2032, by Region
Figure 19: Global Attractiveness Analysis 2022 to 2032, by Region
Figure 20: North America Value (US$ Million) Analysis, 2012 to 2021
Figure 21: North America Value (US$ Million) Forecast, 2022 to 2032
Figure 22: North America Value Share, By Product (2022 E)
Figure 23: North America Value Share, by Application (2022 E)
Figure 24: North America Value Share, by End User (2022 E)
Figure 25: North America Value Share, by Country (2022 E)
Figure 26: North America Attractiveness Analysis, By Product, 2022 to 2032
Figure 27: North America Attractiveness Analysis, By Application, 2022 to 2032
Figure 28: North America Attractiveness Analysis, By End User, 2022 to 2032
Figure 29: North America Attractiveness Analysis, By Country, 2022 to 2032
Figure 30: USA. Value Proportion Analysis, 2022
Figure 31: Global Vs. USAGrowth Comparison, 2021 to 2032
Figure 32: USA Share Analysis (%) By Product, 2021 to 2032
Figure 33: USA Share Analysis (%) by Application, 2021 to 2032
Figure 34: USA Share Analysis (%) by End User, 2021 to 2032
Figure 35: Canada Value Proportion Analysis, 2022
Figure 36: Global Vs. Canada. Growth Comparison, 2021 to 2032
Figure 37: Canada Share Analysis (%) By Product, 2021 to 2032
Figure 38: Canada Share Analysis (%) by Application, 2021 to 2032
Figure 39: Canada Share Analysis (%) by End User, 2021 to 2032
Figure 40: Latin America Value (US$ Million) Analysis, 2012 to 2021
Figure 41: Latin America Value (US$ Million) Forecast, 2022 to 2032
Figure 42: Latin America Value Share, By Product (2022 E)
Figure 43: Latin America Value Share, by Application (2022 E)
Figure 44: Latin America Value Share, by End User (2022 E)
Figure 45: Latin America Value Share, by Country (2022 E)
Figure 46: Latin America Attractiveness Analysis, By Product, 2022 to 2032
Figure 47: Latin America Attractiveness Analysis, By Application, 2022 to 2032
Figure 48: Latin America Attractiveness Analysis, By End User, 2022 to 2032
Figure 49: Latin America Attractiveness Analysis, By Country, 2022 to 2032
Figure 50: Mexico Value Proportion Analysis, 2022
Figure 51: Global Vs. Mexico Growth Comparison, 2021 to 2032
Figure 52: Mexico Share Analysis (%) By Product, 2021 to 2032
Figure 53: Mexico Share Analysis (%) by Application, 2021 to 2032
Figure 54: Mexico Share Analysis (%) by End User, 2021 to 2032
Figure 55: Brazil Value Proportion Analysis, 2021
Figure 56: Global Vs. Brazil. Growth Comparison, 2021 to 2032
Figure 57: Brazil Share Analysis (%) By Product, 2021 to 2032
Figure 58: Brazil Share Analysis (%) by Application, 2021 to 2032
Figure 59: Brazil Share Analysis (%) by End User, 2021 to 2032
Figure 60: Argentina Value Proportion Analysis, 2022
Figure 61: Global Vs. Argentina Growth Comparison, 2021 to 2032
Figure 62: Argentina Share Analysis (%) By Product, 2021 to 2032
Figure 63: Argentina Share Analysis (%) by Application, 2021 to 2032
Figure 64: Argentina Share Analysis (%) by End User, 2021 to 2032
Figure 65: Europe Value (US$ Million) Analysis, 2012 to 2021
Figure 66: Europe Value (US$ Million) Forecast, 2022 to 2032
Figure 67: Europe Value Share, By Product (2022 E)
Figure 68: Europe Value Share, by Application (2022 E)
Figure 69: Europe Value Share, by End User (2022 E)
Figure 70: Europe Value Share, by Country (2022 E)
Figure 71: Europe Attractiveness Analysis, By Product, 2022 to 2032
Figure 72: Europe Attractiveness Analysis, By Application, 2022 to 2032
Figure 73: Europe Attractiveness Analysis, By End User, 2022 to 2032
Figure 74: Europe Attractiveness Analysis, By Country, 2022 to 2032
Figure 75: UK Value Proportion Analysis, 2022
Figure 76: Global Vs. UK Growth Comparison, 2021 to 2032
Figure 77: UK Share Analysis (%) By Product, 2021 to 2032
Figure 78: UK Share Analysis (%) by Application, 2021 to 2032
Figure 79: UK Share Analysis (%) by End User, 2021 to 2032
Figure 80: Germany Value Proportion Analysis, 2022
Figure 81: Global Vs. Germany Growth Comparison, 2021 to 2032
Figure 82: Germany Share Analysis (%) By Product, 2021 to 2032
Figure 83: Germany Share Analysis (%) by Application, 2021 to 2032
Figure 84: Germany Share Analysis (%) by End User, 2021 to 2032
Figure 85: Italy Value Proportion Analysis, 2022
Figure 86 Global Vs. Italy Growth Comparison, 2021 to 2032
Figure 87: Italy Share Analysis (%) By Product, 2021 to 2032
Figure 88: Italy Share Analysis (%) by Application, 2021 to 2032
Figure 89: Italy Share Analysis (%) by End User, 2021 to 2032
Figure 90: France Value Proportion Analysis, 2021
Figure 91: Global Vs. France Growth Comparison, 2021 to 2032
Figure 92: France Share Analysis (%) By Product, 2021 to 2032
Figure 93: France Share Analysis (%) by Application, 2021 to 2032
Figure 94: France Share Analysis (%) by End User, 2021 to 2032
Figure 95: Spain Value Proportion Analysis, 2022
Figure 96: Global Vs. Spain Growth Comparison, 2021 to 2032
Figure 97: Spain Share Analysis (%) By Product, 2021 to 2032
Figure 98: Spain Share Analysis (%) by Application, 2021 to 2032
Figure 99: Spain Share Analysis (%) by End User, 2021 to 2032
Figure 100: Russia Value Proportion Analysis, 2022
Figure 101: Global Vs. Russia Growth Comparison, 2021 to 2032
Figure 102: Russia Share Analysis (%) By Product, 2021 to 2032
Figure 103: Russia Share Analysis (%) by Application, 2021 to 2032
Figure 104: Russia Share Analysis (%) by End User, 2021 to 2032
Figure 105: BENELUX Value Proportion Analysis, 2022
Figure 106: Global Vs. BENELUX Growth Comparison, 2021 to 2032
Figure 107: BENELUX Share Analysis (%) By Product, 2021 to 2032
Figure 108: BENELUX Share Analysis (%) by Application, 2021 to 2032
Figure 109: BENELUX Share Analysis (%) by End User, 2021 to 2032
Figure 110: East Asia Value (US$ Million) Analysis, 2012 to 2021
Figure 111: East Asia Value (US$ Million) Forecast, 2022 to 2032
Figure 112: East Asia Value Share, By Product (2022 E)
Figure 113: East Asia Value Share, by Application (2022 E)
Figure 114: East Asia Value Share, by End User (2022 E)
Figure 115: East Asia Value Share, by Country (2022 E)
Figure 116: East Asia Attractiveness Analysis, By Product, 2022 to 2032
Figure 117: East Asia Attractiveness Analysis, By Application, 2022 to 2032
Figure 118: East Asia Attractiveness Analysis, By End User, 2022 to 2032
Figure 119: East Asia Attractiveness Analysis, By Country, 2022 to 2032
Figure 120: China Value Proportion Analysis, 2022
Figure 121: Global Vs. China Growth Comparison, 2021 to 2032
Figure 122: China Share Analysis (%) By Product, 2021 to 2032
Figure 123: China Share Analysis (%) by Application, 2021 to 2032
Figure 124: China Share Analysis (%) by End User, 2021 to 2032
Figure 125: Japan Value Proportion Analysis, 2022
Figure 126: Global Vs. Japan Growth Comparison, 2021 to 2032
Figure 127: Japan Share Analysis (%) By Product, 2021 to 2032
Figure 128: Japan Share Analysis (%) by Application, 2021 to 2032
Figure 129: Japan Share Analysis (%) by End User, 2021 to 2032
Figure 130: South Korea Value Proportion Analysis, 2022
Figure 131: Global Vs. South Korea Growth Comparison, 2021 to 2032
Figure 132: South Korea Share Analysis (%) By Product, 2021 to 2032
Figure 133: South Korea Share Analysis (%) by Application, 2021 to 2032
Figure 134: South Korea Share Analysis (%) by End User, 2021 to 2032
Figure 135: South Asia Value (US$ Million) Analysis, 2012 to 2021
Figure 136: South Asia Value (US$ Million) Forecast, 2022 to 2032
Figure 137: South Asia Value Share, By Product (2022 E)
Figure 138: South Asia Value Share, by Application (2022 E)
Figure 139: South Asia Value Share, by End User (2022 E)
Figure 140: South Asia Value Share, by Country (2022 E)
Figure 141: South Asia Attractiveness Analysis, By Product, 2022 to 2032
Figure 142: South Asia Attractiveness Analysis, By Application, 2022 to 2032
Figure 143: South Asia Attractiveness Analysis, By End User, 2022 to 2032
Figure 144: South Asia Attractiveness Analysis, By Country, 2022 to 2032
Figure 145: India Value Proportion Analysis, 2022
Figure 146: Global Vs. India Growth Comparison, 2021 to 2032
Figure 147: India Share Analysis (%) By Product, 2021 to 2032
Figure 148: India Share Analysis (%) by Application, 2021 to 2032
Figure 149: India Share Analysis (%) by End User, 2021 to 2032
Figure 150: Indonesia Value Proportion Analysis, 2022
Figure 151: Global Vs. Indonesia Growth Comparison, 2021 to 2032
Figure 152: Indonesia Share Analysis (%) By Product, 2021 to 2032
Figure 153: Indonesia Share Analysis (%) by Application, 2021 to 2032
Figure 154: Indonesia Share Analysis (%) by End User, 2021 to 2032
Figure 155: Malaysia Value Proportion Analysis, 2022
Figure 156: Global Vs. Malaysia Growth Comparison, 2021 to 2032
Figure 157: Malaysia Share Analysis (%) By Product, 2021 to 2032
Figure 158: Malaysia Share Analysis (%) by Application, 2021 to 2032
Figure 159: Malaysia Share Analysis (%) by End User, 2021 to 2032
Figure 160: Thailand Value Proportion Analysis, 2022
Figure 161: Global Vs. Thailand Growth Comparison, 2021 to 2032
Figure 162: Thailand Share Analysis (%) By Product, 2021 to 2032
Figure 163: Thailand Share Analysis (%) by Application, 2021 to 2032
Figure 164: Thailand Share Analysis (%) by End User, 2021 to 2032
Figure 165: Oceania Value (US$ Million) Analysis, 2012 to 2021
Figure 166: Oceania Value (US$ Million) Forecast, 2022 to 2032
Figure 167: Oceania Value Share, By Product (2022 E)
Figure 168: Oceania Value Share, by Application (2022 E)
Figure 169: Oceania Value Share, by End User (2022 E)
Figure 170: Oceania Value Share, by Country (2022 E)
Figure 171: Oceania Attractiveness Analysis, By Product, 2022 to 2032
Figure 172: Oceania Attractiveness Analysis, By Application, 2022 to 2032
Figure 173: Oceania Attractiveness Analysis, By End User, 2022 to 2032
Figure 174: Oceania Attractiveness Analysis, By Country, 2022 to 2032
Figure 175: Australia Value Proportion Analysis, 2022
Figure 176: Global Vs. Australia Growth Comparison, 2021 to 2032
Figure 177: Australia Share Analysis (%) By Product, 2021 to 2032
Figure 178: Australia Share Analysis (%) by Application, 2021 to 2032
Figure 179: Australia Share Analysis (%) by End User, 2021 to 2032
Figure 180: New Zealand Value Proportion Analysis, 2022
Figure 181: Global Vs. New Zealand Growth Comparison, 2021 to 2032
Figure 182: New Zealand Share Analysis (%) By Product, 2021 to 2032
Figure 183: New Zealand Share Analysis (%) by Application, 2021 to 2032
Figure 184: New Zealand Share Analysis (%) by End User, 2021 to 2032
Figure 185: Middle East & Africa Value (US$ Million) Analysis, 2012 to 2021
Figure 186: Middle East & Africa Value (US$ Million) Forecast, 2022 to 2032
Figure 187: Middle East & Africa Value Share, By Product (2022 E)
Figure 188: Middle East & Africa Value Share, by Application (2022 E)
Figure 189: Middle East & Africa Value Share, by End User (2022 E)
Figure 190: Middle East & Africa Value Share, by Country (2022 E)
Figure 191: Middle East & Africa Attractiveness Analysis, By Product, 2022 to 2032
Figure 192: Middle East & Africa Attractiveness Analysis, By Application, 2022 to 2032
Figure 193: Middle East & Africa Attractiveness Analysis, By End User, 2022 to 2032
Figure 194: Middle East & Africa Attractiveness Analysis, By Country, 2022 to 2032
Figure 195: GCC Countries Value Proportion Analysis, 2022
Figure 196: Global Vs. GCC Countries Growth Comparison, 2021 to 2032
Figure 197: GCC Countries Share Analysis (%) By Product, 2021 to 2032
Figure 198: GCC Countries Share Analysis (%) by Application, 2021 to 2032
Figure 199: GCC Countries Share Analysis (%) by End User, 2021 to 2032
Figure 200: Turkey Value Proportion Analysis, 2022
Figure 201: Global Vs. Turkey Growth Comparison, 2021 to 2032
Figure 202: Turkey Share Analysis (%) By Product, 2021 to 2032
Figure 203: Turkey Share Analysis (%) by Application, 2021 to 2032
Figure 204: Turkey Share Analysis (%) by End User, 2021 to 2032
Figure 205: South Africa Value Proportion Analysis, 2022
Figure 206: Global Vs. South Africa Growth Comparison, 2021 to 2032
Figure 207: South Africa Share Analysis (%) By Product, 2021 to 2032
Figure 208: South Africa Share Analysis (%) by Application, 2021 to 2032
Figure 209: South Africa Share Analysis (%) by End User, 2021 to 2032
The global single-photon emission computed tomography market is expected to reach worth USD 2.45 Billion in 2022.
The single-photon emission computed tomography is expected to reach USD 4.76 Billion by the end of 2032, with sales revenue expected to register a growth rate of 6.9% CAGR.
Rapid technological advancements, rise in volume of free standing imaging centers, and expanded applications for single-photon emission computed tomography in oncology are some of the key trends in the single-photon emission computed tomography market.
The USA, Japan, China, Germany, and the Uk are expected to drive demand for single-photon emission computed tomography.
North America, spearheaded by the USA will continue to remain one of the key markets for single-photon emission computed tomography.
Demand for single-photon emission computed tomography in South Asia is expected to grow at 7.7% CAGR over the next ten years.
Demand for single-photon emission computed tomography in Europe is expected to register a growth of 6.8% during the forecast period.
The USA, Japan, and China are the key producers of single-photon emission computed tomography.
Bruker Corp., DDD-Diagnostic AS, Digirad Corp., General Electric Co., Mediso Ltd., MiE GmbH, MILabs BV, Siemens Healthineers AG, Spectrum Dynamics Medical Inc., GE Healthcare, CardiArc, Beijing Hamamatsu Photon Techniques INC., SHENZHEN BASDA, MEDICAL APPARATUS CO., LTD., PNPMed, NuCare Inc. are some of the key players in the single-photon emission computed tomography market.
The market for single-photon emission computed tomography expanded at a CAGR rate of 5.4% during the historical years of 2012 to 2021.
Explore Similar Insights
Single-Photon Emission Computed Tomography Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
